Daré Bioscience Presents Positive Sildenafil Cream, 3.6% Data Supporting Further Development for the Treatment of Female Sexual Arousal Disorder

SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the presentation of positive findings from a previously reported investigational study that used thermography technology to assess the pharmacodynamics of Sildenafil Cream, 3.6% (Sildenafil Cream) in healthy women. The presentation was made at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting 2020, which took place in Orlando, FL, March 5-8, 2020.

Full Article


Daré Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

SAN DIEGO, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the outcome of a Type C meeting with the U.S. Food and Drug Administration (FDA) where alignment was reached on the patient reported outcome (PRO) instruments to be used in a Phase 2b clinical study of Sildenafil Cream, 3.6% (Sildenafil Cream) to screen eligible patients with Female Sexual Arousal Disorder (FSAD) and to assess the efficacy of Sildenafil Cream in treating FSAD. The discussions with the FDA followed the completion of a content validity study of the proposed PRO instruments, a non-interventional study integral to initiating the at-home, product dosing portion of the Sildenafil Cream Phase 2b program.

Full Article


Daré Bioscience and Strategic Science & Technologies Announce Presentation of Positive Findings from Thermography Clinical Study of Sildenafil Cream, 3.6 % in Healthy Women at the Sexual Medicine Society of North America Conference

SAN DIEGO, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced a poster presentation at the Sexual Medicine Society of North America 20th Annual Fall Scientific Meeting, which took place in Nashville, Tennessee, October 24-27, 2019. Daré, in collaboration with SST, is developing Sildenafil Cream, 3.6% as a potential treatment for female sexual arousal disorder (FSAD).

Full Article


Daré Bioscience Announces Completion of its Content Validity Study to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

SAN DIEGO, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the completion of a content validity study, a non-interventional study integral to initiating the at-home, product dosing portion of the Sildenafil Cream, 3.6% (Sildenafil Cream) Phase 2b program. Daré plans to review the findings of the content validity study with the U.S. Food and Drug Administration (FDA) in a Type C meeting and to seek alignment on the patient reported outcome (PRO) instruments to be used to screen eligible patients with Female Sexual Arousal Disorder (FSAD) and to assess the efficacy of Sildenafil Cream in treating FSAD.

Full Article


Daré Bioscience, Inc. Announces Positive Results in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

SAN DIEGO, June 17, 2019 (GLOBE NEWSWIRE) - Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced positive findings from an investigational study designed to evaluate the feasibility of using thermography technology to assess the pharmacodynamics of Sildenafil Cream, 3.6% (Sildenafil Cream) in normal healthy women.

Full Article


Strategic Science & Technologies & Daré announce Initiation of Content Validity Study for Sildenafil Cream, 3.6%

SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) - Daré Bioscience, Inc. (NASDAQ: DARE), a leader in clinical-stage women's health innovation, and SST, a Cambridge, MA based novel topical drug delivery company, today announced the initiation of a content validity study intended to support the use of specific patient reported outcome (PRO) measures to assess efficacy in female sexual arousal disorder (FSAD) patients in the Phase 2b and Phase 3 program for Sildenafil Cream, 3.6%.

Full Article


Strategic Science & Technologies & Daré Bioscience, Inc. Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%

SAN DIEGO, Nov. 27, 2018 (GLOBE NEWSWIRE) - Daré Bioscience, Inc. (NASDAQ: DARE), a leader in clinical-stage women's health innovation, today announced that it is currently enrolling patients in an investigational study designed to evaluate the feasibility of using thermography technology to assess the pharmacodynamics of Sildenafil Cream, 3.6% in normal healthy women. Sildenafil, the active ingredient in Sildenafil Cream, 3.6%, is marketed in an oral dosage form under the brand name Viagra® for the treatment of erectile dysfunction in men. Daré Bioscience, in partnership with Strategic Science & Technologies, LLC (SST), is developing Sildenafil Cream, 3.6% as a potential treatment for female sexual arousal disorder (FSAD).

Full Article


Strategic Science & Technologies & DaréBioscience, Inc. Announces Effective License and Collaboration Agreement for Topical Sildenafil Cream, 3.6%

SAN DIEGO, Feb. 15, 2018 (GLOBE NEWSWIRE) - Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women's biopharmaceutical company, today announced that it has met the funding requirement for obtaining an exclusive worldwide license to advance Sildenafil Citrate Cream 3.6%, a potential treatment for Female Sexual Arousal Disorder (FSAD).

Full Article


Strategic Science & Technologies & Daré Bioscience, Inc. Enters into License and Collaboration Agreement for a Potential First in Class Product

SAN DIEGO - February 12, 2018– Daré Bioscience, Inc. [NASDAQ: DARE], a clinical-stage, women's biopharmaceutical company, today announced it has entered into an agreement to license Sildenafil Cream, 3.6%, a potential treatment for Female Sexual Arousal Disorder (FSAD), from Strategic Science & Technologies, LLC. FSAD is characterized primarily by an inability to attain or maintain sufficient physical sexual arousal that causes distress or interpersonal difficulty.

Full Article


Strategic Science & Technologies Initiates Phase 2 Study to Evaluate Topical Sildenafil in Women with FSAD

CAMBRIDGE, Mass. - October 28, 2015 - Strategic Science & Technologies, a clinical stage biotechnology company developing known pharmaceutical products, announced the initiation of a Phase 2 clinical proof-of-concept trial of sildenafil cream, 3.6%, a first-in-class topical product candidate in development for the treatment of Female Sexual Arousal Disorder. The cream contains sildenafil citrate, the active drug component in Viagra®, which is currently marketed by Pfizer for the treatment of erectile dysfunction in men.

Full Article


Strategic Science & Technologies Initiates Phase 2 Study to Evaluate Topical Sildenafil in Men with ED

CAMBRIDGE, Mass. - June 17, 2015 - Strategic Science & Technologies LLC, a clinical stage biotechnology company developing novel first-in-class topical formulations of known pharmaceutical products, announced the initiation of a Phase 2 trial of topical sildenafil for men with erectile dysfunction. The oral formulation of sildenafil is marketed by Pfizer as Viagra®.

Full Article


Strategic Science & Technologies Announces Completion of Phase 1 Trial for a First-in-Class Treatment for Female Sexual Arousal Disorder

CAMBRIDGE, Mass. - May 15, 2015 - Strategic Science & Technologies LLC, a clinical-stage biotechnology company developing novel first-in-class topical formulations of known pharmaceutical products, announced today the successful completion of a Phase 1 clinical trial of sildenafil cream, 3.6%, the Company's first-in-class topical sildenafil product candidate in development for the treatment of female sexual arousal disorder.

Full Article

Let's Talk   Contact Us